» Articles » PMID: 32210451

HNF-4α Inhibits Hepatocellular Carcinoma Cell Proliferation Through Mir-122-adam17 Pathway

Overview
Journal PLoS One
Date 2020 Mar 27
PMID 32210451
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the most common human cancers, its prevalence and severity need us to discover novel early diagnostic biomarkers and new therapeutic strategies. MicroRNA-122 is the most abundant microRNA in the liver, and acts as a tumor suppressor and represses HCC development. In our study we showed that HNF-4α and MiR-122 were down-regulated significantly in hepatocellular carcinoma. Over-expression of HNF-4α inhibit hepatocellular carcinoma cells proliferation. And miR-122 is one of the downstream effector of HNF-4α. Up-regulated miR-122 inhibited hepatocellular carcinoma cells proliferation through regulating ADAM17. Collectively, our results suggested that HNF-4α could inhibit hepatocellular carcinoma proliferation with miR-122 being a downstream target of it. And miR-122 would inhibit hepatocellular carcinoma proliferation by regulating ADAM17 signal pathway.

Citing Articles

Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications.

Romeo M, Dallio M, Scognamiglio F, Ventriglia L, Cipullo M, Coppola A Cancers (Basel). 2023; 15(21).

PMID: 37958352 PMC: 10647270. DOI: 10.3390/cancers15215178.


ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.

Yang J, Lee I, Huang C, Huang H, Wu Y, Chong Z Int J Mol Sci. 2023; 24(9).

PMID: 37175410 PMC: 10178422. DOI: 10.3390/ijms24097703.


Retraction: HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.

PLoS One. 2023; 18(3):e0283891.

PMID: 36989316 PMC: 10057813. DOI: 10.1371/journal.pone.0283891.


Network pharmacology and experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma.

Cao X, Chen H, Li Z, Li X, Yang X, Jin Q Front Pharmacol. 2022; 13:985084.

PMID: 36133813 PMC: 9483169. DOI: 10.3389/fphar.2022.985084.


Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma.

Chun K Pharmaceutics. 2022; 14(7).

PMID: 35890276 PMC: 9316959. DOI: 10.3390/pharmaceutics14071380.


References
1.
Tsai W, Hsu P, Lai T, Chau G, Lin C, Chen C . MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009; 49(5):1571-82. DOI: 10.1002/hep.22806. View

2.
Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N . Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends. 2013; 7(1):1-6. View

3.
Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

4.
Nakao K, Miyaaki H, Ichikawa T . Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014; 49(4):589-93. DOI: 10.1007/s00535-014-0932-4. View

5.
Shen J, LeFave C, Sirosh I, Siegel A, Tycko B, Santella R . Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas. BMC Med Genomics. 2015; 8:28. PMC: 4460673. DOI: 10.1186/s12920-015-0105-1. View